Blockade of neoangiogenesis, a new and promising technique to control the growth of malignant tumors and their metastases

Current Vascular Pharmacology

Volumn 7, Issue 3, 2009, Pages 347-357

  Grimm, Daniela ^a,b   Bauer, Johann ^c   Schoenberger, Johann ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b AARHUS UNIVERSITY   (Denmark)

^c MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^d UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Angiogenesis; Angiogenesis inhibitor; Cancer; Endothelial cell; Receptor; Signaling; VEGF; Vessels

Indexed keywords

3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; AFLIBERCEPT; ALPHA INTERFERON; ALPHA2B INTERFERON; ANTISENSE OLIGONUCLEOTIDE; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CYCLOPHOSPHAMIDE; DEHYDRODIDEMNIN B; DOCETAXEL; ERLOTINIB; HYBRID PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRINOTECAN; MESSENGER RNA; NEUTRALIZING ANTIBODY; PACLITAXEL; PRAVASTATIN; RECEPTOR ANTIBODY; SEMAXANIB; SORAFENIB; SUNITINIB; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VATALANIB; ANTIBODY; PROTEIN TYROSINE KINASE;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CELL DIFFERENTIATION; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG HALF LIFE; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FIBROBLAST; GASTROINTESTINAL TUMOR; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MULTIPLE MYELOMA; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SOLID TUMOR; TARGET CELL; TUMOR CELL; TUMOR VASCULARIZATION; VASCULARIZATION; ANIMAL; BIOLOGICAL MODEL; DRUG ANTAGONISM; DRUG SCREENING; METHODOLOGY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ANTIBODIES; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN-TYROSINE KINASES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 69149089384     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016109788340640     Document Type: Review

References (122)

1. Folkman J, Cole P, Zimmerman S. Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg 1966; 164: 491-502.
2. Blood CH, Zetter BR. Tumor interactions with the vasculature - Angiogenesis and tumor metastasis. Biochem Biophys Acta 1990; 1032: 89-118.
3. Ohta Y, Tanaka M, Endo Y, Murakami S, Oda M, Sasaki T, et al. Relationship between microlymphatic vessel density within tumors and lymph node metastasis. Oncol Rep 1997; 4: 889-92.
4. O'Connell JX, Nanthakumar SS, Nielsen GP, Rosenberg AE. Osteoid osteoma: The uniquely innervated bone tumor. Mod Pathol 1998; 11: 175-80.
5. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2002; 2: 573-83.
6. Dadras SS, Paul T, Bertoncini J, Brown LF, Muzikansky A, Jackson DG, et al. Tumor lymphangiogenesis - A novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 2003; 162: 1951-60.
7. Jussila L, Valtola R, Partanen TA, Salven P, Heikkila P, Matikainen MT, et al. Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res 1998; 58: 1599-1604.
8. Algire GH, Chalkley HW. Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic implants. J Nat Cancer Inst 1945; 6: 73-85.
9. Greenblatt M, Shubi P. Tumor angiogenesis: transfilter diffusion studies in the hamster by transparent chamber technique. J Nat Cancer Inst 1968; 41: 111-24.
10. Ehrmann RL, Knoth M. Choriocarcinoma: Transfilter stimulation of vasoproliferation in the hamster cheek pouch. Studied by light and electron microscopy. J Nat Cancer Inst 1968; 41: 1329-41.
11. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971; 133: 275-88.
12. Holderfield MT, Hughes CC. Crosstalk between vascular endothelial growth factor, notch, and transforming growth factor-beta in vascular morphogenesis. Circ Res 2008; 102, 637-52.
13. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 2007; 8: 464-78.
14. Grimm D, Bauer J, Infanger M, Cogoli A. The use of the random positioning machine for the study of gravitational effects on signal transduction in mammalian cells. Signal Transduct 2006; 6: 388-96.
15. Infanger M, Kossmehl P, Shakibaei M, Bauer J, Kossmehl-Zorn S, Cogoli A, et al. Simulated weightlessness changes the cytoskeleton and extracellular matrix proteins in papillary thyroid carcinoma cells. Cell Tissue Res 2006; 324: 267-77.
16. Kossmehl P, Shakibaei M, Cogoli A, Infanger M, Curcio F, Schonberger J, et al. Weightlessness induced apoptosis in normal thyroid cells and papillary thyroid carcinoma cells via extrinsic and intrinsic pathways. Endocrinology 2003; 144: 4172-9.
17. Infanger M, Kossmehl P, Shakibaei M, Baatout S, Witzing A, Grosse J, et al. Induction of three-dimensional assembly and increase in apoptosis of human endothelial cells by simulated microgravity: impact of vascular endothelial growth factor. Apoptosis 2006; 11: 749-64.
18. Infanger M, Ulbrich C, Baatout S, Wehland M, Kreutz R, Bauer J, et al. Modeled gravitational unloading induced downregulation of endothelin-1 in human endothelial cells. J Cell Biochem 2007; 101: 1439-55.
19. Ulbrich C, Westphal K, Baatout S, Wehland M, Bauer J, Flick B, et al. Effects of basic fibroblast growth factor on endothelial cells under conditions of simulated microgravity. J Cell Biochem 2008; 104: 1324-41.
20. Shiose S, Hata Y, Noda Y, Sassa Y, Takeda A, Yoshikawa H, et al. Fibrinogen stimulates in vitro angiogenesis by choroidal endothelial cells via autocrine VEGF. Graefes Arch Clin Exp Ophtalmol 2004; 242: 777-83.
21. Kim HK, Song KS, Chung JH, Lee KR, Lee SN. Platelet microparticles induce angiogenesis in vitro. Br J Haematol 2004; 124: 376-84.
22. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
23. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth-factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-45.
24. Rafii S, Lyden D, Benezra R, Hattori K, Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2002; 2: 826-35.
25. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth-factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 1992; 359: 845-48.
26. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011-27.
27. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-85.
28. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-09.
29. Clauss M, Gerlach M, Gerlach H, Brett J, Wang F, Familletti PC, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990; 172: 1535-45.
30. Ray PS, Fox PL. A post-transcriptional pathway represses monocyte VEGF-A expression and angiogenic activity. EMBO J 2007; 26: 3360-72.
31. Lee SJ, Lee HK. Sanguiin H-6 blocks endothelial cell growth through inhibition of VEGF binding to VEGF receptor. Arch Pharm Res 2005; 28: 1270-74.
32. Nakatsu MN, Sainson RC, Pérez-del-Pulgar S, Aoto JN, Aitkenhead M, Taylor KL, et al. VEGF(121) and VEGF(165) regulate blood vessel diameter through vascular endothelial growth factor receptor 2 in an in vitro angiogenesis model. Lab Invest 2003; 83, 1873-85.
33. Huang JZ, Frischer JS, Serur A, Kadenhe A, Yokoi A, McCrudden KW, et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA 2003; 100: 7785-90.
34. Mancuso P, Calleri A, Cassi C, Gobbi A, Capillo M, Pruneri G, et al. Circulating endothelial cells as a novel marker of angiogenesis. Adv Exp Med Biol 2003; 522: 83-97.
35. Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med 1998; 49: 407-24.
36. Toi M, Kondo S, Suzuki H, Yamamoto Y, Inada K, Imazawa T, et al. Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer 1996; 77: 1101-6.
37. Toi M, Hoshina S, Takayanagi T, Tominaga T. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 1994; 85: 1045-9.
38. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20: 4368-80.
39. Oh SJ, Jeltsch MM, Birkenhager R, McCarthy JEG, Weich HA, Christ B, et al. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol 1997; 188: 96-109.
40. Rissanen TT, Markkanen JE, Gruchala M, Heikura T, Puranen A, Kettunen MI, et al. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res 2003; 92: 1098-106.
41. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor families of proteins. Endocr Rev 1992; 13: 18-32.
42. Fairbrother WJ, Champe MA, Christinger HW, Keyt BA, Starovasnik MA. Solution structure of the heparin-binding domain of vascular endothelial growth factor. Structure 1998; 6: 637-48.
43. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. Dual regulation of vascular endothelial growth-factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992; 267: 26031-7.
44. Gengrinovitch S, Greenberg SM, Cohen T, Gitay-Goren H, Rockwell P, Maione TE, et al. Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms. J Biol Chem 1995; 270: 15059-65.
45. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9-22.
46. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996: 15: 290-8.
47. Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 1998; 95: 548-53.
48. Shibuya M. Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). Int J Biochem Cell Biol 2001; 33: 409-20.
49. Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 2007; 19: 2003-12.
50. Millauer B, Wizigman-Voos S, Shnurch H, Martinez R, Moller NPH, Risau W, et al. High-affinity VEGF binding and development expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993; 72: 835-46.
51. Pepper MS, Vassalli JD, Wilks JW, Schweigerer L, Orci L, Montesano R. Modulation of bovine microvascular endothelial-cell proteolytic properties by inhibitors of angiogenesis. J Cell Biochem 1994; 55: 419-34.
52. Wiesmann C, Fuh G, Christinger HW, Eigenbrot C, Wells JA, deVos AM. Crystal structures at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell 1997; 91: 695-704.
53. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/ VEGF receptor system and its role under physiological and pathological conditions. Clin Sci 2005; 109: 227-41.
54. Keyt BA, Nguyen HV, Berleau LT, Duarte CM, Park J, Chen H, et al. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors - Generation of receptor-selective VEGF variants by site-directed mutagenesis. J Biol Chem 1996; 271: 5638-46.
55. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005; 333: 328-35.
56. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, et al. Feasibility of high-flux anticancer drug screen using a diverse panel of cultured human tumor-cell lines. J Nat Cancer Inst 1991; 83: 757-66.
57. Son YJ, Jang JS, Cho YW, Chung H, Park RW, Kwon IC, et al. Biodistribution and anti-tumor efficacy of doxorubicin loaded glycol-chitosan nanoaggregates by EPR effect. J Control Release 2003; 91: 135-45.
58. Mueller-Klieser W. Tumor biology and experimental therapeutics. Crit Rev Oncol Hematol 2000; 36: 123-39.
59. Grimm D, Bauer J, Kromer E, Steinbach P, Riegger G, Hofstadter F. Human follicular and papillary thyroid carcinoma cells interact differently with human venous endothelial cells. Thyroid 1995; 5: 155-64.
60. Schonberger J, Bauer J, Spruss T, Weber G, Chahoud I, Eilles C, et al. Establishment and characterization of the follicular thyroid carcinoma cell line ML-1. J Mol Med 2000; 78: 102-10.
61. Weber G, Grimm D, Bauer J. Application of binary buffer systems to free flow cell electrophoresis. Electrophoresis 2000; 21: 325-28.
62. Obermaier C, Jankowski V, Schmutzler C, Bauer J, Wildgruber R, Infanger M, et al. Free-flow isoelectric focusing of proteins remaining in cell fragments following sonication of thyroid carcinoma cells. Electrophoresis 2005; 26, 2109-16.
63. Grimm D, Bauer J, Kossmehl P, Shakibaei M, Schoenberger J, Pickenhahn H, et al. Simulated microgravity alters differentiation and increases apoptosis in human follicular thyroid carcinoma cells. FASEB J 2002; 16: 604-6.
64. Schoenberger J, Grimm D, Kossmehl P, Infanger M, Kurth E, Eilles C. Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: An animal study. Endocrinology 2004; 145: 1031-38.
65. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 1006; 93: 14765-70.
66. Whitehurst B, Flister MJ, Bagaitkar J, Volk L, Bivens CM, Pickett B, et al. Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model. Int J Cancer 2007; 121: 2181-91.
67. Manning EA, Ullman JGM, Leatherman JM, Asquith JM, Hansen TR, Armstrong TD, et al. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res 2007; 13: 3951-59.
68. McCormack PL, Keam SJ. Bevacizumab - A review of its use in metastatic colorectal cancer. Drugs 2008; 68: 487-506.
69. Muller YA, Chen Y, Christinger HW, Li B, Cunningham BC, Lowman HB, et al. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 angstrom resolution and mutational analysis of the interface. Structure 1998; 6: 1153-67.
70. Sathornsumetee S, Rich JN. Antiangiogenic therapy in malignant glioma: promise and challenge. Curr Pharm Des 2007; 13: 3545-58.
71. Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 2008; 26: 399-405.
72. Garcia AA, Hirte H, Fleming G, Yang DY, Tsao-Wei DD, Roman L, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and princess Margaret hospital phase II consortia. J Clin Oncol 2008; 26: 76-82.
73. Hainsworth JD, Spigel DR, Sosman JA, Burris HA, Farley C, Cucullu H, et al. Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial. Clin Genitourin Cancer 2007; 5: 427-32.
74. Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory nonsmall-cell lung cancer. J Clin Oncol 2007; 25: 4743-50.
75. Ramaswamy B, Elias AD, Kelbick NT, Dodley A, Morrow M, Hauger M, et al. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res 2006; 12, 3124-29.
76. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastastic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
77. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab vs. paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-76.
78. Koontz BF, Miles EF, Rubio MAD, Madden JF, Fisher SR, Scher RL, et al. Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: Two case studies. Head Neck 2008; 30: 262-66.
79. Zwolak P, Dudek AZ, Bodempudi VD, Nguyen J, Hebbel RP, Gallus NJ, et al. Local irradiation in combination with bevacizumab enhances radiation control of bone destruction and cancer-induced pain in a model of bone metastases. Int J Cancer 2008; 122: 681-8.
80. Goldman CK, Kendall RL, Cabrera G, Soroceanu L, Heike Y, Gillespie GY, et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 1998; 95: 8795-800.
81. Yamaguchi T, Bando H, Mori T, Takahashi K, Matsumoto H, Yasutome M, et al. Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: Association with progression and prognosis. Cancer Sci 2007; 98: 405-10.
82. Toi M, Bando H, Ogawa T, Muta M, Hornig C, Weich HA. Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer. Int J Cancer 2002; 98: 14-18.
83. Kommareddy S, Amiji M. Antiangiogenic gene therapy with systemically administered sFlt-1 plasmid DNA in engineered gelatin-based nanovectors. Cancer Gene Ther 2007; 14: 488-98.
84. Makinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI, Pulkkanen KJ, et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med 2001; 7: 199-205.
85. Lin P, Sankar S, Shan S, Dewhirst MW, Polverini PJ, Quinn TQ, et al. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ 1998; 9: 49-58.
86. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, et al. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002; 99: 11393-8.
87. Huang JZ, Frischer JS, Serur A, Kadenhe A, Yokoi A, McCrudden KW, et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA 2003; 100: 7785-90.
88. Lu C, Thaker PH, Lin YG, Spannuth W, Landen CN, Merritt WM, et al. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. Am J Obstet Gynecol 2008; 198: 477.e1-9; discussion 477.e9-10.
89. Verheul HMW, Hammers H, Van Erp K, Wei Y, Sanni T, Salumbides B, et al. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res 2007; 13: 4201-8.
90. Wachsberger PR, Burd R, Cardi C, Thakur M, Daskalakis C, Holash J, et al. VEGF trap in combination with radiotherapy improves tumor control in U87 glioblastoma. Int J Radiat Oncol Biol Physics 2007; 67: 1526-37.
91. Kureishi Y, Luo ZY, Shiojima I, Bialik A, Fulton D, Lefer DJ, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 6: 1004-10.
92. Cudmore M, Ahmad S, Al-Ani B, Fujisawa T, Coxall H, Chudasama K, et al. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation 2007; 115: 1789-97.
93. Kodama Y, Kitta Y, Nakamura T, Takano H, Umetani K, Fujioka D, et al. Atorvastatin increases plasma soluble Fms-like tyrosine kinase-1 and decreases vascular endothelial growth factor and placental growth factor in association with improvement of ventricular function in acute myocardial infarction. J Am Coll Cardiol 2006; 48: 43-50.
94. Kusuyama T, Omura T, Nishiya D, Enomoto S, Matsumoto R, Murata T, et al. The effects of HMG-CoA reductase inhibitor on vascular progenitor cells. J Pharmacol Sci 2006; 101: 344-49.
95. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-34.
96. Ryan CW, Goldman BH, Lara PN, Mack PC, Beer TM, Tangen CM, et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol 2007; 25: 3296-301.
97. Kiura K, Nakagawa K, Shinkai T, Eguchi K, Ohe Y, Yamamoto N, et al. A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol 2008; 3: 386-93.
98. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 2516-24.
99. Laurie SA, Gauthier I, Arnold A, Shepherd FA, Ellis PM, Chen E, et al. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the national cancer institute of Canada clinical trials group. J Clin Oncol 2008; 26: 1871-8.
100. Cohen RB, Langer CJ, Simon GR, Eisenberg PD, Hainsworth JD, Madajewicz S, et al. A phase I randomized phase II, noncomparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC). Cancer Chemother Pharmacol 2007; 60: 81-9.
101. Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 2007; 13, 2643-50.
102. Kovacs MJ, Reece DE, Marcellus D, Meyer RM, Mathews S, Dong RP, et al. A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma - NCIC CTG IND.145. Invest New Drugs 2006; 24: 529-35.
103. Fury MG, Zahalsky A, Wong R, Venkatraman E, Lis E, Hann L, et al. A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers. Invest New Drugs 2007; 25: 165-72.
104. van Spronsen DJ, De Mulder PH. Targeted approaches for treating advanced clear cell renal carcinoma. Onkologie 2006; 29: 394-402.
105. Joshi DD, Banerjee T. Vascular endothelial growth factor (VEGF) receptor antibody bevacizumab (Avastin) induces regression of renal cell carcinoma in an adolescent resulting in residual tumorectomy. Pediatr Blood Cancer 2008; 50: 903-4.
106. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7: 987-89.
107. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
108. Los M, Roodhart JML, Voest EE. Target practice: Lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 2007; 12: 443-50.
109. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005; 69 (Suppl 3): 4-10.
110. Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res 2005; 65: 3967-79.
111. Ribatti D, Vacca A, Roncali L, Dammaco F. Angiogenesis under normal and pathological conditions. Haematologica 1991; 76, 311-20.
112. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003; 9: 685-93.
113. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-8.
114. Rooney P, Kumar S, Ponting J, Wang M. The role of hyaluronan in tumour neovascularization. Int J Cancer 1995; 60: 632-6.
115. Tryggvason K, Hoyhtya M, Salo T. Proteolytic degradation of extracellular matrix in tumor invasion. Biochem Biophys Acta 1987; 907: 191-217.
116. Tabernero J. The role of VEGF and EGFR inhibition: Implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 2007; 5: 203-20.
117. Henke E, Perk J, Vider J, de Candia P, Chin Y, Solit DB, et al. Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. Nat Biotechnol 2008; 26: 91-100.
118. Straight AM, Oakley K, Moores R, Bauer AJ, Patel A, Tuttle RM, et al. Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several. Cancer Chemotherap Pharmacol 2006, 57: 7-14.
119. Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 2005; 23: 5464-73.
120. Cai W, Rao J, Gambhir SS, Chen X. How molecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther 2006; 5: 2624-33.
121. Chan LW, Moses MA, Goley E, Sproull M, Muanza T, Coleman CN, et al. Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. J Clin Oncol 2004; 22: 499-506.
122. Smith ER, Zurakowski D, Saad A, Scott RM, Moses MA. Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res 2008; 14: 2378-86.